Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
4
×
new york blog main
new york top stories
4
×
boston blog main
boston top stories
drugs
san diego blog main
san diego top stories
akcea therapeutics
biotech
clinical trials
inotersen
new york
patisiran
san francisco blog main
san francisco top stories
tafamidis
accelerator
airbnb
alnylam pharmaceuticals
amarin
amazon web services (aws)
anylam pharmaceuticals
artificial intelligence (a.i.)
athelas
atomwise
attack
barry greene
benchling
biotechnology
boston
boston university
cancer
cardiomyopathy
cardiovascular
cholesterol
coinbase
coworking
What
ago
4
×
alnylam
big
fda
patients
abuzz
admits
akcea
amarin
amyloidosis
approve
approved
attr
available
awaits
battle
biological
biotechs
classes
clinical
combinator
community
companies
crossed
debilitating
decades
decision
deeper
discovered
disease
dive
doctors
drug
dug
eager
fingers
fish
friday
genetic
gives
Language
unset
Current search:
ago
×
" national top stories "
×
" new york top stories "
×
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Deeper Dive: Amarin Fish-Oil Study Gives Eager Doctors More to Ponder
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision